Cardiovascular safety of lercanidipine in patients with angina pectoris: A review of six randomized clinical trials

Current Therapeutic Research - Clinical and Experimental

Volumn 62, Issue 1, 2001, Pages 3-15

  Specchia, Giuseppe ^a,b   Saccaggi, Silvia Pia ^b   Ghezzi, Cristina ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b Policlinico di Monza   (Italy)

^c Recordati SpA   (Italy)

Author keywords

Angina; Calcium antagonist; Lercanidipine; Safety

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; LERCANIDIPINE; PLACEBO;

ANGINA PECTORIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT;

EID: 0034999259     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(01)80037-0     Document Type: Article

References (33)

1. 1999 World Health Organization-International society of hypertension guidelines for the management of hypertension. Guidelines Subcommittee
2. Chronic coronary artery disease
3. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris
4. Medical therapy of chronic stable angina pectoris
5. Selection of drug therapy in stable angina pectoris
6. The risk of myocardial infarction associated with antihypertensive drug therapies
7. How safe are calcium antagonists in hypertension and coronary heart disease?
8. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
9. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
10. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension
11. The sixth report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
12. Lercanidipine: Short plasma half-life, long duration of action
13. In vitro calcium antagonist activity of lercanidipine and its enantiomers
14. In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers
15. Lercanidipine protects the heart from low-flow ischemia damage and antagonizes the vasopressor activity of endothelin-1
16. Time dependence of the cardioprotective effects of lercanidipine
17. Effects of lercanidipine and its enantiomers on ischemia and reperfusion
18. Hemodynamic effects and power spectral analysis of heart rate and arterial pressure variabilities induced by lercanidipine in conscious dogs
19. Activity of lercanidipine administered in single and repeated doses once-daily as monitored over 24 hours in patients with mild to moderate hypertension
20. Efficacy and tolerability of lercanidipine vs captopril in patients with mild to moderate hypertension in a double-blind controlled study
21. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double-blind controlled study
22. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements
23. Clinical advantages of lipophilic dihydropyridines
24. The pharmacological properties of lipophilic calcium antagonists
25. Lercanidipine: A novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity
26. The safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: Current experience with lercanidipine
27. Acute dose-response, double-blind, placebo-controlled pilot study of lercanidipine in patients with angina pectoris
28. Nifedipine and mortality. Grave defects in the dossier
29. Mortality differences between ACE inhibitor and calcium channel blocker treated hypertensive patients
30. Selective use of calcium channel blockers to treat high risk hypertensive patients
31. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients
32. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study
33. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)